Drug intelligence / Profile preview

SAL023

Development stage: Phase 1
Lead developer: Shenzhen Salubris Pharmaceuticals
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

SAL023 is a biosimilar monoclonal antibody being developed by Shenzhen Salubris Pharmaceuticals for the treatment of osteoporosis. It acts as a sclerostin (SOST) inhibitor, mimicking the mechanism of action of the reference product, romosozumab (Evenity). By binding to and inhibiting sclerostin, SAL023 promotes bone formation and decreases bone resorption, thereby increasing bone mineral density. It is currently undergoing Phase 1 clinical trials in China to establish pharmacokinetic, pharmacodynamic, safety, and immunogenicity biosimilarity to Italy-manufactured Evenity.

Other names: romosozumab biosimilar

Targets

SOST (Sclerostin)

Beyond the preview

Go deeper on SAL023.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SAL023.

Explore the full profile